Home › Funds › Cormorant Asset Management, LP › FTH
Cormorant Asset Management, LP position in FTH
FAETH THERAPEUTICS INC
Cormorant Asset Management, LP reported holding 1,028,242 shares of FTH (FAETH THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$30.6M, representing 2.19% of its reported portfolio and ranking #15 among its reported holdings. Cormorant Asset Management, LP has disclosed FTH holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's FTH position evolved
Cormorant Asset Management, LP first disclosed a stake in FTH in Q1 2026 at 306,222 shares (US$9.7M). The position peaked in Q3 2026 at 1,028,242 shares, worth US$30.6M. Across 3 filings, Cormorant Asset Management, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,028,242 shares valued at US$30.6M. Notable position changes include a 236% increase in Q2 2026 (shares rose 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 306.22K | $9.65M | New |
| Q2 2026 | 1.03M | $7.66M | Add |
| Q3 2026 | 1.03M | $30.58M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FTH and 13F data
FTH (FAETH THERAPEUTICS INC) is a company whose sector is not yet classified in our data. 78 other funds we track also report a position in FTH — the largest reported positions include MONTANOVA CAPITAL, LLC (US$68.7M), Avoro Capital Advisors LLC (US$41.9M), Trails Edge Capital Partners, LP (US$28.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FTH
- MONTANOVA CAPITAL, LLC 2.31M sh · $68.72M · Q3 2026
- Avoro Capital Advisors LLC 1.41M sh · $41.93M · Q3 2026
- Trails Edge Capital Partners, LP 941.69K sh · $28.01M · Q3 2026
- Caligan Partners LP 890.21K sh · $26.47M · Q3 2026
- Vivo Capital, LLC 844.58K sh · $25.12M · Q3 2026
- BAKER BROS. ADVISORS LP 803.42K sh · $23.89M · Q3 2026
- Fairmount Funds Management LLC 722.02K sh · $21.47M · Q3 2026
- B Group, Inc. 610.17K sh · $18.15M · Q3 2026
- STEMPOINT CAPITAL LP 404.92K sh · $12.04M · Q3 2026
- Ikarian Capital, LLC 199.69K sh · $5.94M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 124.10K sh · $3.69M · Q3 2026
- Octagon Capital Advisors LP 100.00K sh · $2.97M · Q3 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held FTH?
Cormorant Asset Management, LP has disclosed FTH holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Cormorant Asset Management, LP's current position in FTH?
As of Q3 2026, Cormorant Asset Management, LP holds 1.03M shares of FTH (FAETH THERAPEUTICS INC), valued at $30.58M, representing 2.19% of its reported portfolio and ranking #15.
Has Cormorant Asset Management, LP been buying or selling FTH?
In the latest 13F filing (Q3 2026), Cormorant Asset Management, LP held unchanged its position in FTH. The position peaked in Q3 2026 at 1.03M shares.
Which other funds hold FTH?
Other major institutional holders of FTH include MONTANOVA CAPITAL, LLC, Avoro Capital Advisors LLC, Trails Edge Capital Partners, LP, among 78 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.